Cytomx Therapeutics, Inc. · NASDAQ:CTMX
Cytomx Therapeutics — Investor Presentation (January 2018)
24 slides from Cytomx Therapeutics's investor presentation, Jan 8, 2018
Slide 1: Corporate Overview: Reinventing Therapeutic Antibodies for the Treatment of Cancer
CORPORATE OVERVIEW: REINVENTING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER January 2018 © 2018 CytomX Therapeutics, Inc. Exhibit 99.1
Slide 2: Forward Looking Statements
Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding
Slide 3: Validating Partnerships; Innovative Probody Platform; Well-Funded
Validating Partnerships Partnerships with leading oncology players such as AbbVie, Amgen, BMS ~$400 million in upfront and milestone payments received to date Retained co-development rights and profit splits on certain products Leveraging Our Innovative Probody Platform to Build a Pipeline of Differ
Slide 4: Strong Execution Throughout 2017
Strong Execution Throughout 2017 CX-072 (PD-L1) CX-2009 (CD166) CX-2029 (CD71) BMS-986249 (CTLA-4) Partnerships PROCLAIM-CX-2009 Monotherapy dose escalation recruiting PROCLAIM-CX-072 Completed monotherapy dose escalation enrollment (Part A1) All combinations arms recruiting First monotherapy cohort
Slide 5: Deep and Differentiated Probody Pipeline with Initial Data Read Outs Anticipated in 2018
PRODUCT CANDIDATE LEAD OPTIMIZATION IND-ENABLING PHASE 1/2 PARTNER CX-072 CX-2009 BMS-986249 CX-2029 CX-188 T Cell Bispecific Additional PDCs, IO, TCBs Deep and Differentiated Probody Pipeline with Initial Data Read Outs Anticipated in 2018 Immunotherapies Probody Drug Conjugates T Cell Engaging Bis
Slide 6: Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment
Probody Therapeutics are Designed to be Activated in the Tumor Microenvironment ANTI-CANCER ANTIBODY LINKER MASKING PEPTIDE PROTEASES
Slide 7: 2018 Clinical Goal: Preliminary Proof of Concept
Presence of Target & Protease Activity 2018 Clinical Goal: Preliminary Proof of Concept Target Engagement by Probody Cleavage of Probody in Tumors Antibody Protease Substrate Linker Mask Initial assessment to include: Probody PK, stability of mask in circulation Probody activation in tumor tissue In
Slide 8: Immuno-Oncology Programs CX-072 (PD-L1) BMS-986249 (CTLA-4)
IMMUNO-ONCOLOGY PROGRAMS CX-072 (PD-L1) BMS-986249 (CTLA-4)
Slide 9: Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities
Full Potential for Combination Immunotherapy is Limited by Immune-Related Toxicities DERMATITIS PNEUMONITIS HEPATITIS THROMBOEMBOLIC OCULAR TOXICITY HYPOPHYSITIS THYROIDITIS COLITIS, DIARRHEA NEUROPATHY * Melanoma Nivolumab Mono Ipilimumab Mono Nivo + Ipi Combo ORR 44% 19% 58% Grade 3 and 4 AEs* 16%
Slide 10: CX-072 as a Potential Centerpiece of Combination Cancer Therapy
CX-072 as a Potential Centerpiece of Combination Cancer Therapy CX-072 PD-L1 PROBODY THERAPEUTIC Checkpoint Inhibitors E.g. Yervoy® Probody Tx PDCs Pb-TCBs Other Cancer Immuno- therapies Kinase Inhibitors E.g. Zelboraf® ADCs Validated target Well-established efficacy & safety for class
Slide 11: PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination
PROCLAIM-072: Phase 1/2 CX-072 Assessment as Monotherapy and in Combination Initial Clinical Data Expected Mid-2018 Inclusion: Unselected cancer types Dose: 0.3 – 30 mg/kg + IPI (3 and 10 mg/kg) A1: DOSE ESCALATION Inclusion: PD naïve, unselected cancer types Dose: 0.03 – 30 mg/kg A2: MANDATORY BIOP
Slide 12: CX-072 Preclinical Proof of Concept
Non-binding Control Antibody Parent PD-L1 Antibody CX-072 PD-L1 Probody Tx Tumor CX-072 Preclinical Proof of Concept TUMOR GROWTH SAFETY Induction of Autoimmunity Prevents Binding in Periphery Autoimmunity Reduced Similar Efficacy Localizes to Tumor Tx Tx
Slide 13: Phase 1/2 Study of BMS-986249 (anti-CTLA-4 Probody Therapeutic)
Phase 1/2 Study of BMS-986249 (anti-CTLA-4 Probody Therapeutic)
Slide 14: CTLA-4 Probody Tx Demonstrates Similar Efficacy with Improved Safety in Preclinical Studies
CTLA-4 Probody Tx Demonstrates Similar Efficacy with Improved Safety in Preclinical Studies Control 0/10 Tumor Free Ipilimumab 7/10 Tumor Free Ipilimumab Pb Tx 6/10 Tumor Free Similar Anti-Tumor Efficacy Less Peripheral T-Cell Activation Percentage of Ki-67+ CD4+ T-cells Vehicle Anti-CTLA-4 (ipilimu
Slide 15: Probody Drug Conjugate Programs CX-2009 (Anti-CD166) CX-2029 (Anti-CD71)
PROBODY DRUG CONJUGATE PROGRAMS CX-2009 (ANTI-CD166) CX-2029 (ANTI-CD71)
Slide 16: Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets
Probody Technology Enables Selection of Better Antibody Drug Conjugate Targets PDC Targets May Have More Attractive Attributes: CD166 CD71 Her2 CD30 Mesothelin Folate Receptor CD166 PDC Targets ADC Targets ADC Targets are Limited Based on Healthy Tissue Expression: More patients More indications Sou
Slide 17: PROCLAIM-CX-2009: Anti-CD166 PDC Phase 1/2 Clinical Trial Design
2017 2018 PROCLAIM-CX-2009: Anti-CD166 PDC Phase 1/2 Clinical Trial Design Breast cancer Castration-resistant prostate cancer Cholangiocarcinoma Endometrial cancer Head and neck cancer Non-small cell lung cancer Ovarian cancer Lung cancer Breast cancer Ovarian cancer Seven CD166+ tumor types in mono
Slide 18: CX-2009: A Probody Drug Conjugate Targeting CD166 Preclinical Proof of Concept
CX-2009: A Probody Drug Conjugate Targeting CD166 Preclinical Proof of Concept CX2009 CD166 Antibody DM4 Payload V1 V2 C1 C2 C3 Cancer Cell Substrate Linker Mask Protease GLP Toxicity Study Results: Dosed up to 15 mg/kg in cynos Observed toxicity consistent with typical DM4 payload toxicity
Slide 19: CD71 is a High Potential Target for a Probody Drug Conjugate
CD71 is a High Potential Target for a Probody Drug Conjugate Ubiquitously expressed on dividing, normal and malignant cells Mediates iron uptake required for cell division A professional internalizing protein: often used as a positive control in ADC experiments Expression in normal dividing cells pr
Slide 20: Probody Platform Has the Potential to Enable CD71 as a Drug Conjugate Target
Probody Platform Has the Potential to Enable CD71 as a Drug Conjugate Target Partnered with AbbVie: Co-development rights and profit split IND anticipated in 1H 2018 PDC regresses tumors after a single dose PDC has efficacy across almost all preclinical models Models tested 42 Regression or stasis 3
Slide 21: CytomX Therapeutics
Aw es ai, ++ cx CYTOMX THERAPEUTICS
Slide 22: Deep and Differentiated Probody Pipeline with Initial Data Read Outs Anticipated in 2018
PRODUCT CANDIDATE LEAD OPTIMIZATION IND-ENABLING PHASE 1/2 PARTNER CX-072 CX-2009 BMS-986249 CX-2029 CX-188 T Cell Bispecific Additional PDCs, IO, TCBs Deep and Differentiated Probody Pipeline with Initial Data Read Outs Anticipated in 2018 Immunotherapies Probody Drug Conjugates T Cell Engaging Bis
Slide 23: Alliances Have Brought Significant Capital into CytomX and Broadened Our Pipeline
Alliances Have Brought Significant Capital into CytomX and Broadened Our Pipeline of Probody Therapeutics 10 oncology, 2 non-oncology targets CTLA-4 Probody Tx in Ph. 1 $287 million earned to date $4.8 billion in potential milestones, tiered royalties up to low-double digits EGFR-TCB + 3 additional
Slide 24: Five Programs Anticipated in the Clinic by End of 2018
Five Programs Anticipated in the Clinic by End of 2018 Well-Funded Validating Pharma Partners Well-Funded Milestones Expected in 2018 Strong cash position to advance pipeline Funding into 2020 CX-072 initial clinical readout mid-year (wholly owned) CX-2009 initial clinical readout in 2H’18 (wholly o
CytomX Therapeutics — Investor Presentation (January 2018) on 6ix